“Cosciens Shares Dive Following Phase III Trial Setback for Growth Hormone Treatment”
Cosciens, a biotechnology firm, recently experienced a 32% stock price decline after its growth hormone test failed to meet the primary endpoint in a Phase III clinical trial. The study…